

## RECFIVED 1860 0 4 1998 GROUP 1800

Sheet 1 of 3

Form PTO-1449 (Substituted) (REV. 8-83)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SERIAL NO. 09/053,872

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)											APPLICANTS Eric Rose, et al.				
											FILING DATE April 1, 1998	GROUP <del>1049</del> なうろ			
									U.	S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
							Г								
		$\vdash$										1			
		$\vdash$	П		_		$\vdash$	Τ				1	<b></b>		
		<del>                                     </del>	Н					<del> </del>				<del> </del>			
<b></b> -	-	┼──	H			-	$\vdash$	一				<u> </u>			
<b></b> -		<del>                                     </del>	H			-	$\vdash$					<del> </del>	<del></del>		
<b></b> -		-	H			-		-				1			
			H		_	-	┝	<del>                                     </del>				<del> </del>			
<u> </u>		<del> </del>	H			-	_	-							
<b> </b> -		-	H				-	-				<del> </del>	<b> </b>		
<u></u>	<u> </u>	<u>L</u>					<u> </u>	<u> </u>	FOR				L		
	FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION  COUNTRY CLASS SUBCL												ATION		
		DOCUMENT NUMBER				BER		DATE	COUNTRY	02,00		Yes No			
			П												
			П					Γ							
	<b></b>	<u> </u>	Ll	O'	TH	ER	L L De	 በር	IIMENT	S (Including Author, Title, Date, Pert	inent Pages Etc	<del></del>		<u> </u>	
\\ \alpha \\ \al	Π	Baz	an							in blood coagulation, l		<del></del>	<del></del>		
M									96;		,				
FL		Benedict, C.R. et al., Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model, J. Clin. Invest.,													
	88:1760-1765, 1991;														
EXAMIN	VER (	Jes	Fa	مے	E.	lų	Sse		DATE CON	SIDERED November 3, 2001					
*EXAMIN	ER: I	nitial	if	cit	ati	on c	onsi	ider	ed, whether	r or not citation is in conformance with	n MPEP 609: Draw	line thr	ough cita	ation	

Sheet 2 of 3



U.S. DEPARTMENT OF COMMERCE SO634-B/JPW/JML/YL SERIAL NO. Form PTO-1449 (Substituted) 09/053,872 PATENT AND TRADEMARK OFFICE (REV. 8-83) APPLICANTS Eric Rose, et al. INFORMATION DISCLOSURE CITATION GROUP FILING DATE (Use several sheets if necessary) 1643 1653 April 1, 1998 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R., et al., Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Texas Heart Institute Journal, 21: 86-90, 1994; Berntorp, E., Biochemical and in vivo properties of high purity factor IX concentrates, Thrombosis and Haemostasis, 70(5):768-773, 11/1993; Freedman, S.J. et al., Structure of the metal-free y-carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy, J. Biol. Chem., 270(14):7980-7987, 04/1995; Furie, B.C. and Furie, B. (1995) Biosynthesis of factor IX: implications for gene therapy, Thrombosis and Haemostasis, 74(1):274-277; Iberti, T.J. et al., Abnormal coagulation profile in brain tumor patients during surgery, Neurosurgery, 34(3):389-395, 03/1994; Kirchhofer, et al. (1995) Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model, Arterioscler. Thromb. Vasc. Biol., 15:1098-1106; Kuwabara, K. et al., Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries, J. Biol. Chem., 270(14):8179-8187, 04/1995; Miyata, T. et al., Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling, Brit. J. Of Haematol., 88(1):156-165, 09/1994; E. Russel DATE CONSIDERED November 3, 2001 EXAMINER

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## GROUP 1800

Sheet 2 of 3 ATTY, DOCKET NO. SERIAL NO: Form PTO-1449 (Substituted) U.S. DEPARTMENT OF COMMERCE 50634-B/JPW/JML/YL 09/053,872 (REV. 8-83) PATENT AND TRADEMARK OFFICE APPLICANTS Eric Rose, et al. INFORMATION DISCLOSURE CITATION FILING DATE GROUP (Use several sheets if necessary) 1643 1653 April 1, 1998 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R., et al., Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Texas Heart Institute Journal, 21: 86-90, 1994; Berntorp, E., Biochemical and in vivo properties of high purity factor IX concentrates, Thrombosis and Haemostasis, 70(5):768-773, 11/1993; Freedman, S.J. et al., Structure of the metal-free y-carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy, J. Biol. Chem., 270(14):7980-7987, 04/1995; Furie, B.C. and Furie, B. (1995) Biosynthesis of factor IX: implications for gene therapy, Thrombosis and Haemostasis, 74(1):274-277; Iberti, T.J. et al., Abnormal coagulation profile in brain tumor patients during surgery, Neurosurgery, 34(3):389-395, 03/1994; Kirchhofer, et al. (1995) Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model, Arterioscler. Thromb. Vasc. Biol., 15:1098-1106; Kuwabara, K. et al., Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries, J. Biol. Chem., 270(14):8179-8187, 04/1995; Miyata, T. et al., Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling, Brit. J. Of Haematol., 88(1):156-165, 09/1994; EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.



## RECFIVED SECTIVED GROUP 1800

Sheet\_3\_ of\_3

SERIAL NO. ATTY, DOCKET NO. Form PTO-1449 (Substituted) U.S. DEPARTMENT OF COMMERCE 50634-B/JPW/JML/YL 09/053,872 PATENT AND TRADEMARK OFFICE (REV. 8-83) APPLICANTS Eric Rose, et al. INFORMATION DISCLOSURE CITATION FILING DATE GROUP (Use several sheets if necessary) 1643 1653 April 1, 1998 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Santagostino, E. et al., Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery, Thrombosis and Haemostasis, 71(6):737-40, 06/1994; Wacey, A.I. et al., Determinants of the factor IX mutational spectrum in hemophilia B: an analysis of missense mutations using a multidomain molecular model of the activated protein, Hum. Genet., 94(6):594-608, 12/1994; Warrier, I. et al., Safety of high doses of a monoclonal antibodypurified factor IX concentrate, Am. J. Of Hematol., 49(1):92-94, 05/1995; Wong, A. G. et al., Relative efficacy of active site-blocked factors IXa Xa in a model of venous thrombosis, Supplement I Circulation, Abstract # 3293 p. I-686, Vol. 92 No. 8, 10/1995; DATE CONSIDERED EXAMINER ~ November 3, 2001

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.